MAPT and Parkinson disease: Accumulating evidences suggest that HSF1 mitigates α-synuclein toxicity 46, inhibits the polyglutamine aggregation 117, and prevents Tau-related pathologies 118, thereby delaying the progression of Parkinson's disease (PD), Huntington's disease (HD) and Alzheimer's disease (AD), respectively (Fig. 2B).